FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer

Novocure's Optune Pax, a wearable Tumor Treating Fields device, received U.S. Food and Drug Administration approval for adult patients with locally advanced pancreatic cancer when used concomitantly with gemcitabine and nab-paclitaxel. The approval is supported by the randomized, open-label PANOVA-3 phase III clinical trial (n=571), which met its primary endpoint: median overall survival (OS) 16.2 vs 14.2 months (hazard ratio [HR] 0.82; p=0.039).

The FDA approved Optune Pax via the premarket approval (PMA) pathway, its most rigorous device review process, based on a pivotal study run under an investigational device exemption. The agency described the OS improvement as approximately two months versus chemotherapy alone and highlighted localized skin reactions as the most common device-related risk. Optune Pax is a portable, wearable medical device that delivers Tumor Treating Fields (TTFields), alternating electric fields intended to disrupt cancer cell proliferation. Safety was dominated by localized, device-related skin reactions and did not appear to add systemic chemotherapy toxicity; the most important practical constraint is wear time, recommended at about 18 hours/day, with trial median usage reported at 62.1%, making adherence a key real-world variable.

In the PANOVA-3 trial, median overall survival in the modified per-protocol analysis was 18.3 months in the Optune Pax plus gemcitabine/nab-paclitaxel arm versus 15.1 months with chemotherapy alone (HR 0.77; p=0.023). Efficacy results were statistically significant for OS and pain outcomes, but selective: the publication reports no improvement in progression-free survival, local progression-free survival, or objective response rate, despite the OS and pain-free survival findings.

Separately, Novocure earned a CE mark for Optune Pax in Europe for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with guideline recommendations. With the CE mark secured, the company plans to launch Optune Pax in Germany in the coming weeks. The system is also under evaluation in the PANOVA-4 study for metastatic pancreatic cancer.

Baar, Switzerland-based Novocure develops the Optune platform for delivering tumor treating fields to treat cancer. The Optune Pax device delivers TTFields non-invasively through wearable arrays; the alternating electrical fields target the electrical properties of cancer cells to disrupt processes critical for cancer cell division and survival, leading to cell death without significantly affecting healthy cells. The platform also has approval for non-small cell lung cancer.

The company's senior vice president for EMEA and Canada said: "The CE Mark designation is a critical milestone in our efforts to bring Optune Pax to people living with locally advanced pancreatic cancer, a disease in need of new treatment options. We are proud of this achievement and are committed to working with national agencies to secure access to Optune Pax for patients with pancreatic cancer who may benefit from treatment."

The head of the Department of Medical Oncology at Hospital Clínic Barcelona said: "Pancreatic cancer is often diagnosed in late stages when tumors are more difficult to treat. As a result, treatment options have limited effect and survival rates have remained low for decades. However, in the Phase 3 PANOVA-3 trial for Optune Pax, a statistically significant improvement in overall survival was observed in patients who were at an advanced stage of disease. In addition, Optune Pax was also shown to delay pain progression, a debilitating symptom of pancreatic cancer. This is a promising treatment for patients who have an urgent need for new options."

The market treated the FDA approval as a material catalyst: Novocure shares finished up about 19% on February 12, 2026, after the Optune Pax FDA approval news.